Dermaliq Therapeutics, Inc.

Background

Dermaliq Therapeutics, Inc., established in 2021 as a spin-off from Novaliq GmbH, is a private, clinical-stage pharmaceutical company specializing in dermatology and medical aesthetics. The company's mission is to develop a new generation of superior topical therapeutics and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients.

Key Strategic Focus

Dermaliq's strategic focus centers on leveraging its proprietary hyliQ® technology to enhance targeted penetration of active ingredients into skin tissues, thereby improving treatment efficacy and reducing side effects. The company specializes in developing topical therapies for follicular diseases and conditions, including androgenetic alopecia, alopecia areata, and plaque psoriasis.

Financials and Funding

In January 2022, Dermaliq secured a $15 million Series A financing round led by 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. The proceeds are allocated to advancing three Phase 1/2a clinical dermatology programs.

Pipeline Development

Dermaliq's pipeline includes:

DLQ01: A topical prostaglandin F2α analog for treating androgenetic alopecia. Phase 1b/2a trials demonstrated a 12.3% increase in target area hair counts over six months, with 83% of subjects responding positively.

DLQ02: A topical calcineurin inhibitor targeting plaque psoriasis. A Phase 1b/2a trial commenced in August 2022 to evaluate safety and efficacy.

DLQ03: A broad-spectrum topical antibiotic aimed at accelerating wound healing and preventing secondary infections. Phase 2 data indicated a 20-25% faster wound healing compared to the vehicle.

Technological Platform and Innovation

Dermaliq's proprietary hyliQ® technology enables cutaneous drug delivery with unmatched bioavailability. This platform facilitates the development of superior liquid therapeutic drugs characterized by exceptional cosmetic properties and eliminates the need for skin-irritating excipients like preservatives or penetration enhancers.

Leadership Team

Dr. Frank Löscher: CEO, President & Co-Founder. Formerly Chief Technology Officer at Novaliq GmbH, instrumental in developing several drug candidates and products.

Dr. Oliver Schlüter: CFO & Co-Founder. Also serves as CFO of Novaliq, with over 25 years of experience in finance and life sciences.

Dr. Betsy Hughes-Formella: CSO & Co-Founder. Nearly three decades of experience in developing topical products and transdermals for various indications.

Leadership Changes

In February 2025, Dermaliq appointed Dr. Ralf Paus to its Scientific and Medical Advisory Board to advance alopecia drug development.

Competitor Profile

Market Insights and Dynamics

The dermatology market is experiencing significant growth, driven by increasing prevalence of skin conditions and advancements in treatment options. The global dermatology market is projected to reach substantial figures by 2025, with a compound annual growth rate (CAGR) reflecting robust demand.

Competitor Analysis

Key competitors include:

Arcutis Biotherapeutics: Focuses on developing treatments for immune-mediated dermatological diseases.

Incyte Corporation: Engages in the discovery, development, and commercialization of proprietary therapeutics, including dermatology products.

Strategic Collaborations and Partnerships

In May 2025, Dermaliq entered into a strategic collaboration with DEBRA Research to advance cutaneous drug delivery for Epidermolysis Bullosa, focusing on developing innovative topical treatments and drug therapies for wound healing and itch relief.

Operational Insights

Dermaliq's proprietary hyliQ® technology provides a competitive advantage by enabling targeted drug delivery into skin tissues, enhancing efficacy, and reducing side effects. This positions the company favorably against competitors in the dermatology market.

Strategic Opportunities and Future Directions

Dermaliq aims to expand its pipeline by leveraging the hyliQ® technology to develop treatments for additional dermatological conditions. The company is actively seeking strategic partners and investors for its current Series B financing round to support the continued development of its innovative dermatology pipeline.